Abbott Laboratories (ABT) Receives FDA Clearance and CE Mark for Next-Generation Ultreon™ 3.0 Software

robot
Abstract generation in progress

Abbott Laboratories (ABT) has received FDA clearance and CE Mark for its Ultreon™ 3.0 Software, an AI-powered imaging platform. This software integrates coronary imaging with AI-automated insights to assist doctors in performing minimally invasive procedures for blocked heart arteries, aiming to improve patient outcomes and reduce risks. An interventional cardiologist noted that the platform helps physicians quickly understand blockages and create actionable treatment plans.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin